CyberKnife is a form of external beam radiation therapy that uses a robotic arm to deliver high doses of radiation to the prostate with sub-millimeter precision. Unlike traditional radiation, which typically requires 30 to 40 sessions over two months, CyberKnife completes treatment in just 4 or 5 sessions over one to two weeks. It’s designed for men with early-stage, localized prostate cancer and offers cancer control rates comparable to other treatments, with a shorter time commitment and a different side effect profile.
How the Technology Works
CyberKnife is the brand name of a machine that delivers stereotactic body radiation therapy (SBRT). At its core is a compact linear accelerator, the device that generates the radiation beam, mounted on a robotic arm. That arm can move freely around the patient, delivering radiation from thousands of different angles. This lets the system shape radiation doses tightly around the prostate while minimizing exposure to surrounding tissue like the bladder and rectum.
What sets CyberKnife apart from conventional radiation machines is its real-time tracking. The prostate shifts slightly as you breathe and as your bladder and bowel fill and empty. CyberKnife tracks these movements continuously during treatment and adjusts the beam accordingly. To make this tracking possible, small gold markers called fiducial markers are placed inside the prostate before treatment begins. Typically 3 to 6 of these tiny radio-opaque seeds are implanted using ultrasound guidance. During each session, the system detects these markers and uses them as reference points to keep the radiation locked on target.
Because the beam is so precisely aimed, each session delivers a much higher dose of radiation than a conventional session would. Fewer total sessions are needed, which is why the entire course can be completed in days rather than months.
What Treatment Looks Like
The first step is a planning phase. Your care team will place the fiducial markers inside the prostate, usually a week or two before treatment begins. A CT scan creates a detailed map of the prostate so the treatment plan can be customized to your anatomy.
Treatment itself is entirely outpatient. You lie on a table while the robotic arm moves around you, and each session lasts between 30 and 90 minutes depending on the size and shape of the treatment area. Most prostate cancer patients receive 4 or 5 sessions total. You don’t need anesthesia, and most men drive themselves home afterward. The entire course wraps up in one to two weeks, compared to the 8 to 10 weeks required for conventional external beam radiation.
Who Is a Good Candidate
CyberKnife works best for men with early-stage prostate cancer that is still confined to the prostate. The treatment area needs to be relatively small, and the prostate itself should be under 80 to 100 cubic centimeters in volume. Men with larger prostates or cancer that has spread beyond the gland are generally not ideal candidates for this approach.
In practice, most men treated with CyberKnife have low-risk or intermediate-risk disease. Your oncologist will evaluate factors like your PSA level, biopsy results, and imaging to determine whether you’re a fit. CyberKnife can also be used as a “boost,” delivering a concentrated dose to the prostate alongside a broader course of conventional radiation, though this approach carries a somewhat different side effect profile.
Cancer Control Rates
Long-term data on CyberKnife for prostate cancer is encouraging. In one of the largest and most mature clinical studies, led by Dr. Donald Fuller, 10-year biochemical recurrence-free survival was 100% for low-risk patients and 84.3% for intermediate-risk patients. Biochemical recurrence-free survival means that PSA levels stayed low enough to indicate no detectable return of cancer over that period. These results are competitive with surgery and other forms of radiation therapy for localized disease.
Side Effects During and After Treatment
Like all prostate radiation treatments, CyberKnife can irritate the urinary tract and the rectum. The most common short-term side effects are increased urinary frequency, urgency, and mild rectal discomfort. In clinical studies of acute toxicity, about 21% of patients experienced moderate or greater urinary symptoms, and about 13% reported moderate or greater bowel symptoms. When CyberKnife was used alone (not as a boost alongside conventional radiation), moderate urinary toxicity dropped to around 10%, and no patients reported moderate bowel toxicity.
These side effects are typically temporary, peaking in the weeks following treatment and gradually improving over the following months. Severe complications requiring intervention are uncommon.
Sexual Function
Erectile function is a major concern for men weighing prostate cancer treatment options. The PACE-A trial, the first randomized study to compare SBRT (including CyberKnife) head-to-head with surgery for early-stage prostate cancer, found that men treated with SBRT reported better sexual function at two years than men who had surgery. The trial enrolled 123 men across 10 UK centers. While radiation can still affect erectile function over time, the degree of impact is generally less than with surgical removal of the prostate, which directly disrupts the nerves controlling erections.
CyberKnife vs. Other Treatment Options
The main alternatives for localized prostate cancer are conventional external beam radiation, surgery (radical prostatectomy), brachytherapy (radioactive seeds placed inside the prostate), and active surveillance for very low-risk disease. CyberKnife’s primary advantages over conventional radiation are convenience and precision. Five sessions over a week or two is a dramatically lighter commitment than 40 sessions over two months, and the tighter beam may reduce collateral damage to nearby organs.
Compared to surgery, CyberKnife avoids the risks of a major operation, including anesthesia, blood loss, infection, and a recovery period of several weeks. The PACE-A trial data suggests it also preserves urinary and sexual function better in the short to medium term. On the other hand, surgery provides a tissue sample that gives definitive information about the cancer’s characteristics, and PSA monitoring after surgery is more straightforward since any detectable PSA may signal recurrence.
Compared to brachytherapy, CyberKnife is completely noninvasive beyond the initial fiducial marker placement. Both deliver concentrated radiation to the prostate, but CyberKnife does so from outside the body. The choice between them often comes down to institutional availability, physician expertise, and individual patient factors like prostate size.
What Recovery Looks Like
There is no surgical recovery period with CyberKnife. Most men return to normal activities within days of completing treatment. Urinary symptoms like frequency and mild burning tend to peak one to three weeks after the final session and then gradually subside. Bowel irritation, if it occurs, follows a similar timeline. Your PSA will be monitored regularly in the months and years after treatment, and it typically declines slowly over 12 to 24 months before stabilizing at a low level.
Some men experience a temporary PSA “bounce,” a brief rise in PSA that does not indicate cancer recurrence but can cause anxiety if you’re not expecting it. Your oncology team will help you distinguish a bounce from a true recurrence based on the pattern and magnitude of the change.